Diamond Equity Research valuation A$0.48 per share, page-10

“Doesn't seem to be much point reading it.”

Whether it’s Diamond Equity Research, Bell Potter or Roth, I take the actual valuation with a grain of salt.

We have seen time and time again valuations/12 month targets being reached in days, weeks or months - and in one case reached prior to publication.

However, these coverage / reports / valuations contain information.

This particular document IS worth reading and is well written. It provides an excellent discussion, exposition and analysis of what Imugene is doing. It looks at the reason for combination strategies ‘now’ as a means of staying ahead of our competitors. It identifies some competitors, the risk that Imugene faces, and the very positive direction being taken.

If truly positive news abounds either in November or the near future as anticipated by many, the price target of $0.48c will be eclipsed.

Whether that happens or not, this document provides a great, understandable summary of what we have invested in. It is a worthy read irrespective of the fact that IMU has paid for a report to be be prepared, and irrespective of the valuation.

Go Imugene

PDS